Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

Shares of BCLI stock opened at $1.15 on Thursday. Brainstorm Cell Therapeutics has a 12 month low of $1.05 and a 12 month high of $11.25. The firm’s 50-day moving average is $1.62 and its two-hundred day moving average is $1.91. The company has a market capitalization of $6.56 million, a PE ratio of -0.24 and a beta of 0.75.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.